Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 24, 2022
Context: This filing serves to distribute two press releases issued on February 24, 2022. The primary release details the Company's Fourth Quarter and Full Year 2021 financial results. The second release announces the appointment of Dr. Mathias Hukkelhoven to the Board of Directors.
Key Financial Metrics
The Form 6-K text provided acts as a cover document and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) but are not explicitly stated in the filing text itself.
Material Changes
- Board Composition: The Company announced the appointment of Dr. Mathias Hukkelhoven to its Board of Directors.
- Financial Performance: The filing references the release of Q4 and Full Year 2021 results, but the specific material changes in financial performance versus prior periods are not detailed in this text.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward-Looking Statement" section from the attached press releases. However, the specific content of the guidance, outlook, management commentary, risks, or contingencies is not included in the provided text. The filing notes that quotes from the CEO, Chairman, and the new Board member are excluded from the incorporation by reference into the Form F-3 Registration Statement.
Investor Verification Checklist
- Review Exhibit 99.1 for specific Q4 and Full Year 2021 revenue, net loss, and cash position figures.
- Verify the specific qualifications and background of the newly appointed Board member, Dr. Mathias Hukkelhoven.
- Examine the "Forward-Looking Statement" in the press releases for updated guidance on clinical trial timelines and cash runway.
- Confirm the status of the Form F-3 Registration Statement (File No. 333-240183) regarding the incorporation of the press release data.